apl-1501
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 21, 2020 (NCT04601766)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LSD1/CoREST complexINHIBITOR
LSD1/CoREST complex inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06435039 | Phase 1 | Jun 26, 2024 | Jiangsu Asieris Pharmaceutical Technology Co., Ltd., Syneos Health |
| NCT06034015 | Phase 1 | Sep 9, 2023 | Jiangsu Asieris Pharmaceutical Technology Co., Ltd. |
| NCT04601766 | Phase 1 | Oct 21, 2020 | Jiangsu Asieris Pharmaceutical Technology Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Asieris Pharmaceutical Technology Co., Ltd. | For profit | 3 | 2 | 1 | 2020 |
| Syneos Health | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1